Scientific leader with extensive experience in target biology, drug discovery and preclinical drug development of small molecule drug candidates against various target classes and in multiple therapeutic areas.
Proven track record of scientific and organizational leadership by helping to discover and deliver multiple novel preclinical candidates in oncology, metabolic disease and inflammation and contribution to several development candidates that entered clinical trials, including TAK-901 (Aurora kinase) and TAK-659 (SYK) in oncology.
An effective functional area leader that built, led and managed all activities of in vitro and cellular pharmacology teams in executing cellular screening, MOA determination and pharmacodynamic assays in support of identification and characterization of small molecule therapeutics. 
Goal-oriented, driven preclinical expert of integrated clinical development teams and provided bridging translational preclinical research to enable clinical development activities.
Evaluated, selected and coordinated CROs in support of internal projects spanning in vitro, cellular and in vivo pharmacology and managed research collaborations with external academic groups.
An excellent written and oral communicator with a track record that includes >30 peer reviewed publications and presentations.

Demonstrated expertise: cellular assays and technologies, in vivo pharmacology, target assessment and validation, drug discovery, project leadership and management.

Available for independent consulting to pharmaceutical and biotech organizations on all aspects of target biology and validation, drug discovery, cell based assay development and validation, interpretation of data and establishing mechanism of action, in vivo pharmacology, from program conception to IND.